SHSE:603567 (China)
Class A
Â¥
11.29
+0.060 (+0.53%)
Apr 3
What is a stock summary page? Click here for an overview.
Business Description
HeiLongJiang ZBD Pharmaceutical Co Ltd
ISIN : CNE100002219
Share Class Description:
SHSE:603567: Class ACompare
Compare
Traded in other countries / regions
603567.China Index Membership
SSE Composite Index IPO Date
2015-04-24Description
HeiLongJiang ZBD Pharmaceutical Co Ltd operates as a pharmaceutical manufacturer. The business scope of the company includes wholesale, retail, traditional Chinese medicine decoction pieces, Chinese medicine formula granules, Chinese herbal medicine trade, medical equipment, sanitary materials, and inspection and testing.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.28 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.43 | |||||
| Debt-to-EBITDA | 4.1 | |||||
| Interest Coverage | 5.81 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.73 | |||||
| Beneish M-Score | -2.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.9 | |||||
| 3-Year EBITDA Growth Rate | -4.8 | |||||
| 3-Year FCF Growth Rate | 10.1 | |||||
| 3-Year Book Growth Rate | 7.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.61 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.34 | |||||
| 9-Day RSI | 55.31 | |||||
| 14-Day RSI | 54.47 | |||||
| 3-1 Month Momentum % | -5.49 | |||||
| 6-1 Month Momentum % | -12.51 | |||||
| 12-1 Month Momentum % | -2.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.69 | |||||
| Quick Ratio | 2.23 | |||||
| Cash Ratio | 0.34 | |||||
| Days Inventory | 214.17 | |||||
| Days Sales Outstanding | 338.52 | |||||
| Days Payable | 69.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.78 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| 3-Year Dividend Growth Rate | -49.5 | |||||
| Forward Dividend Yield % | 1.78 | |||||
| 5-Year Yield-on-Cost % | 1.76 | |||||
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | -1.42 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.56 | |||||
| Operating Margin % | 25.66 | |||||
| Net Margin % | 20.93 | |||||
| FCF Margin % | -9.52 | |||||
| ROE % | 8.51 | |||||
| ROA % | 5.22 | |||||
| ROIC % | 7.2 | |||||
| 3-Year ROIIC % | -12.47 | |||||
| ROC (Joel Greenblatt) % | 16.74 | |||||
| ROCE % | 8.46 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.24 | |||||
| Forward PE Ratio | 17.37 | |||||
| PE Ratio without NRI | 11.66 | |||||
| Shiller PE Ratio | 17.92 | |||||
| Price-to-Owner-Earnings | 23.46 | |||||
| PS Ratio | 3.3 | |||||
| PB Ratio | 1.37 | |||||
| Price-to-Tangible-Book | 1.58 | |||||
| EV-to-EBIT | 16.49 | |||||
| EV-to-EBITDA | 16.49 | |||||
| EV-to-Revenue | 4.31 | |||||
| EV-to-FCF | -45 | |||||
| Price-to-GF-Value | 1.03 | |||||
| Price-to-Projected-FCF | 7.06 | |||||
| Price-to-Graham-Number | 0.9 | |||||
| Price-to-Net-Current-Asset-Value | 4.17 | |||||
| Earnings Yield (Greenblatt) % | 6.06 | |||||
| FCF Yield % | -2.8 | |||||
| Forward Rate of Return (Yacktman) % | -10.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
HeiLongJiang ZBD Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,121.21 | ||
| EPS (TTM) (Â¥) | 0.695 | ||
| Beta | 0.77 | ||
| 3-Year Sharpe Ratio | -0.23 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 29.31 | ||
| 14-Day RSI | 54.47 | ||
| 14-Day ATR (Â¥) | 0.21553 | ||
| 20-Day SMA (Â¥) | 11.115 | ||
| 12-1 Month Momentum % | -2.61 | ||
| 52-Week Range (Â¥) | 9.81 - 13.63 | ||
| Shares Outstanding (Mil) | 941.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HeiLongJiang ZBD Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HeiLongJiang ZBD Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
HeiLongJiang ZBD Pharmaceutical Co Ltd Frequently Asked Questions
What is HeiLongJiang ZBD Pharmaceutical Co Ltd(SHSE:603567)'s stock price today?
The current price of SHSE:603567 is ¥11.29. The 52 week high of SHSE:603567 is ¥13.63 and 52 week low is ¥9.81.
When is next earnings date of HeiLongJiang ZBD Pharmaceutical Co Ltd(SHSE:603567)?
The next earnings date of HeiLongJiang ZBD Pharmaceutical Co Ltd(SHSE:603567) is .
Does HeiLongJiang ZBD Pharmaceutical Co Ltd(SHSE:603567) pay dividends? If so, how much?
The Dividend Yield % of HeiLongJiang ZBD Pharmaceutical Co Ltd(SHSE:603567) is 1.78% (As of Today), Highest Dividend Payout Ratio of HeiLongJiang ZBD Pharmaceutical Co Ltd(SHSE:603567) was 0.6. The lowest was 0.06. And the median was 0.42. The Forward Dividend Yield % of HeiLongJiang ZBD Pharmaceutical Co Ltd(SHSE:603567) is 1.78%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers